Theravance Biopharma (TBPH) Financials

$11.01 -0.11 (-0.99%)

As of 02:33 PM Eastern

Annual Income Statements for Theravance Biopharma

This table shows Theravance Biopharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-56	-55	872
Consolidated Net Income / (Loss)	-56	-55	872
Net Income / (Loss) Continuing Operations	-56	-55	-93
Total Pre-Tax Income	-45	-49	-93
Total Operating Income	-47	-56	-92
Total Gross Profit	64	57	51
Total Revenue	64	57	51
Operating Revenue	64	57	51
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	111	113	143
Selling, General & Admin Expense	69	70	67
Research & Development Expense	38	41	63
Impairment Charge	4.51	0.00	-
Restructuring Charge	0.00	2.74	13
Total Other Income / (Expense), net	2.34	6.77	-0.86
Interest Expense	2.55	2.35	9.40
Other Income / (Expense), net	4.88	9.12	8.55
Income Tax Expense	12	5.92	0.01
Basic Earnings per Share	($1.15)	($1.00)	$11.85
Weighted Average Basic Shares Outstanding	48.85M	55.30M	73.59M
Diluted Earnings per Share	($1.15)	($1.00)	$11.85
Weighted Average Diluted Shares Outstanding	48.85M	55.30M	73.59M
Weighted Average Basic & Diluted Shares Outstanding	49.47M	48.16M	62.86M

This table shows Theravance Biopharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-16	-13	-17	-12	-8.51	-8.95	-16	-22	-10	917
Consolidated Net Income / (Loss)	-16	-13	-17	-12	-8.51	-8.95	-16	-22	-10	917
Net Income / (Loss) Continuing Operations	-16	-13	-17	-12	-8.51	-8.95	-16	-22	-14	-16
Total Pre-Tax Income	-8.94	-10	-15	-10	-5.02	-7.58	-14	-22	-14	-16
Total Operating Income	-9.20	-11	-16	-11	-6.24	-8.76	-16	-25	-17	-14
Total Gross Profit	19	17	14	15	18	16	14	10	15	12
Total Revenue	19	17	14	15	18	16	14	10	15	12
Operating Revenue	19	17	14	15	18	16	14	10	15	12
Total Operating Expenses	28	28	30	26	24	24	30	35	32	27
Selling, General & Admin Expense	19	17	17	17	15	16	19	19	17	16
Research & Development Expense	9.45	9.27	9.95	8.97	8.31	8.31	9.43	15	15	9.87
Total Other Income / (Expense), net	0.26	0.79	0.48	0.81	1.22	1.18	1.94	2.43	3.17	-1.82
Interest Expense	0.64	0.63	0.64	0.63	0.62	0.61	0.57	0.55	0.55	4.58
Other Income / (Expense), net	0.90	1.42	1.13	1.43	1.85	1.79	2.50	2.98	3.72	2.76
Income Tax Expense	6.59	2.65	1.31	1.26	3.49	1.37	1.46	-0.40	-0.51	0.00
Basic Earnings per Share	($0.31)	($0.26)	($0.34)	($0.24)	($0.20)	($0.17)	($0.28)	($0.35)	$0.16	$12.14
Weighted Average Basic Shares Outstanding	48.85M	49.04M	48.75M	48.28M	55.30M	52.36M	56.68M	62.93M	73.59M	75.52M
Diluted Earnings per Share	($0.31)	($0.26)	($0.34)	($0.24)	($0.20)	($0.17)	($0.28)	($0.35)	$0.16	$12.14
Weighted Average Diluted Shares Outstanding	48.85M	49.04M	48.75M	48.28M	55.30M	52.36M	56.68M	62.93M	73.59M	75.52M
Weighted Average Basic & Diluted Shares Outstanding	49.47M	49.17M	48.92M	48.63M	48.16M	49.80M	52.81M	57.80M	62.86M	67.37M

This table details how cash moves in and out of Theravance Biopharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	-1.75	-259	208
Net Cash From Operating Activities	-12	-27	-187
Net Cash From Continuing Operating Activities	-12	-27	-2.43
Net Income / (Loss) Continuing Operations	-56	-55	-93
Consolidated Net Income / (Loss)	-56	-55	872
Depreciation Expense	1.71	2.00	3.72
Amortization Expense	1.91	2.26	3.99
Non-Cash Adjustments To Reconcile Net Income	29	25	42
Changes in Operating Assets and Liabilities, net	12	-0.60	41
Net Cash From Investing Activities	12	-33	1,154
Net Cash From Continuing Investing Activities	12	-33	59
Purchase of Property, Plant & Equipment	-0.33	-2.49	-0.57
Purchase of Investments	-141	-135	-103
Sale of Property, Plant & Equipment	0.00	1.51	1.87
Sale and/or Maturity of Investments	156	103	158
Other Investing Activities, net	-2.29	0.00	-
Net Cash From Financing Activities	-2.50	-199	-759
Net Cash From Continuing Financing Activities	-2.50	-199	-739
Repurchase of Common Equity	-0.45	-197	-129
Issuance of Common Equity	0.61	0.62	0.80
Other Financing Activities, net	-2.66	-2.50	21
Cash Income Taxes Paid	0.11	0.02	118

This table details how cash moves in and out of Theravance Biopharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	14	-23	-7.49	14	-32	-34	-82	-111	-120	331
Net Cash From Operating Activities	-0.90	-5.20	-4.42	-1.02	-0.85	-2.49	-12	-11	-124	-22
Net Cash From Continuing Operating Activities	-0.90	-5.20	-5.44	0.00	-0.85	-2.49	-24	0.00	55	-17
Net Income / (Loss) Continuing Operations	-16	-13	-17	-12	-8.51	-8.95	-16	-22	-14	-16
Consolidated Net Income / (Loss)	-16	-13	-17	-12	-8.51	-8.95	-16	-22	-10	917
Depreciation Expense	0.42	0.43	0.43	0.43	0.39	0.43	0.55	0.63	0.66	1.11
Amortization Expense	0.27	0.33	0.55	0.75	1.03	0.51	0.37	0.35	1.71	0.97
Non-Cash Adjustments To Reconcile Net Income	10	4.73	7.20	7.19	3.81	3.60	6.11	11	3.87	9.88
Changes in Operating Assets and Liabilities, net	3.60	2.01	3.94	2.28	2.43	1.93	-3.82	-1.14	63	-13
Net Cash From Investing Activities	16	-17	-3.03	17	-0.68	-0.02	11	-43	39	1,075
Net Cash From Continuing Investing Activities	16	-17	14	0.00	-0.68	-0.02	-32	0.00	39	-20
Purchase of Property, Plant & Equipment	-0.19	-0.02	-0.04	-0.09	-0.68	-0.02	-0.85	-0.94	-0.27	0.06
Purchase of Investments	-38	-45	-31	-27	-	-	-0.00	-135	-9.89	-39
Sale and/or Maturity of Investments	56	27	28	44	-	-	11	92	49	17
Net Cash From Financing Activities	-0.37	-0.37	-0.04	-1.72	-31	-31	-81	-56	-35	-722
Net Cash From Continuing Financing Activities	-0.37	-0.37	-1.76	0.00	-31	-31	-137	0.00	-35	-702
Issuance of Common Equity	0.16	0.03	-	-	0.17	-0.00	-	-	0.31	0.00
Other Financing Activities, net	-0.53	-0.40	-0.46	-1.27	-0.52	-0.51	-0.58	-0.89	-0.99	24
Cash Income Taxes Paid	0.10	-	0.02	-0.01	0.01	-	0.01	0.01	118	0.00

This table presents Theravance Biopharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	354	382	607
Total Current Assets	161	134	353
Cash & Equivalents	38	40	298
Short-Term Investments	51	63	29
Prepaid Expenses	4.28	14	9.20
Other Current Assets	68	17	17
Plant, Property, & Equipment, net	7.42	9.07	12
Total Noncurrent Assets	186	239	242
Other Noncurrent Operating Assets	186	239	242
Total Liabilities & Shareholders' Equity	354	382	607
Total Liabilities	179	169	166
Total Current Liabilities	32	25	29
Accounts Payable	2.24	1.52	1.55
Accrued Expenses	6.26	6.39	10
Current Deferred & Payable Income Tax Liabilities	5.85	0.00	-
Current Employee Benefit Liabilities	7.02	6.44	10
Other Current Liabilities	11	10	6.75
Total Noncurrent Liabilities	147	144	137
Noncurrent Deferred & Payable Income Tax Liabilities	75	65	64
Other Noncurrent Operating Liabilities	71	79	73
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	176	213	442
Total Preferred & Common Equity	176	213	442
Preferred Stock	0.00	0.00	0.00
Total Common Equity	176	213	442
Common Stock	1,141	1,122	1,296
Retained Earnings	-966	-909	-854
Accumulated Other Comprehensive Income / (Loss)	0.01	-0.07	-0.02

This table presents Theravance Biopharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	356	362	371	414	447	539	763
Total Current Assets	116	119	124	162	192	261	512
Cash & Equivalents	23	46	54	72	106	188	419
Short-Term Investments	68	50	46	62	62	54	68
Prepaid Expenses	8.27	8.93	9.66	11	8.76	7.81	11
Other Current Assets	17	14	15	17	16	12	14
Plant, Property, & Equipment, net	7.79	8.14	8.72	9.29	9.55	12	12
Total Noncurrent Assets	232	235	238	243	245	265	240
Other Noncurrent Operating Assets	232	235	238	243	245	246	240
Total Liabilities & Shareholders' Equity	356	362	371	414	447	539	763
Total Liabilities	170	168	166	167	166	168	283
Total Current Liabilities	23	23	22	25	25	26	142
Accounts Payable	1.45	1.67	1.69	2.37	1.57	2.66	5.34
Accrued Expenses	3.45	4.79	4.95	6.69	8.42	11	7.97
Current Employee Benefit Liabilities	7.84	5.77	4.48	6.58	5.37	5.03	7.56
Other Current Liabilities	11	11	11	9.71	9.16	7.43	0.69
Total Noncurrent Liabilities	147	145	145	142	142	142	141
Noncurrent Deferred & Payable Income Tax Liabilities	72	69	67	66	65	64	63
Other Noncurrent Operating Liabilities	75	76	78	76	77	77	78
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	186	194	205	246	280	371	481
Total Preferred & Common Equity	186	194	205	246	280	371	481
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	186	194	205	246	280	371	481
Common Stock	1,136	1,131	1,126	1,147	1,172	1,247	1,324
Retained Earnings	-950	-937	-921	-901	-892	-876	-844
Accumulated Other Comprehensive Income / (Loss)	0.05	-0.02	-0.04	-0.23	-0.29	0.05	-0.12

This table displays calculated financial ratios and metrics derived from Theravance Biopharma's official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	12.12%	11.84%	-7.17%
EBITDA Growth	9.87%	43.65%	69.48%
EBIT Growth	10.34%	43.75%	67.50%
NOPAT Growth	16.21%	39.06%	64.33%
Net Income Growth	-2.22%	-106.33%	537.32%
EPS Growth	-15.00%	-108.44%	512.89%
Operating Cash Flow Growth	57.27%	85.56%	10.04%
Free Cash Flow Firm Growth	73.25%	92.02%	-62.34%
Invested Capital Growth	-21.14%	-3.28%	143.01%
Revenue Q/Q Growth	1.88%	5.35%	-0.58%
EBITDA Q/Q Growth	-20.43%	16.40%	36.33%
EBIT Q/Q Growth	-10.23%	16.57%	33.55%
NOPAT Q/Q Growth	-6.73%	16.65%	29.64%
Net Income Q/Q Growth	-14.20%	3.25%	2.55%
EPS Q/Q Growth	-10.58%	-56.25%	4.50%
Operating Cash Flow Q/Q Growth	-0.42%	82.03%	-77.46%
Free Cash Flow Firm Q/Q Growth	26.76%	78.56%	-4.83%
Invested Capital Q/Q Growth	-7.53%	-1.39%	1,927.89%
Profitability Metrics	-	-	-
Gross Margin	100.00%	100.00%	100.00%
EBITDA Margin	-59.73%	-74.29%	-147.44%
Operating Margin	-72.92%	-97.58%	-179.09%
EBIT Margin	-65.34%	-81.71%	-162.45%
Profit (Net Income) Margin	-87.63%	-96.11%	1,698.54%
Tax Burden Percent	126.46%	112.02%	-939.65%
Interest Burden Percent	106.05%	105.01%	111.27%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-33.24%	-34.88%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-8.54%	-27.46%	0.00%
Return on Net Nonoperating Assets (RNNOA)	4.19%	18.03%	0.00%
Return on Equity (ROE)	-29.04%	-16.86%	1,689.74%
Cash Return on Invested Capital (CROIC)	-9.60%	-31.55%	-388.84%
Operating Return on Assets (OROA)	-11.43%	-9.48%	-16.98%
Return on Assets (ROA)	-15.33%	-11.16%	177.58%
Return on Common Equity (ROCE)	-29.04%	-16.86%	1,689.74%
Return on Equity Simple (ROE_SIMPLE)	-32.14%	-25.91%	197.40%
Net Operating Profit after Tax (NOPAT)	-33	-39	-64
NOPAT Margin	-51.05%	-68.31%	-125.37%
Net Nonoperating Expense Percent (NNEP)	-24.69%	-7.43%	735.30%
Return On Investment Capital (ROIC_SIMPLE)	-18.72%	-18.42%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	107.44%	122.07%	130.63%
R&D to Revenue	58.47%	70.74%	123.46%
Operating Expenses to Revenue	172.92%	197.58%	279.09%
Earnings before Interest and Taxes (EBIT)	-42	-47	-83
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-38	-43	-76
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	2.64	2.63	1.71
Price to Tangible Book Value (P/TBV)	2.64	2.63	1.71
Price to Revenue (P/Rev)	7.19	9.75	14.72
Price to Earnings (P/E)	0.00	0.00	0.87
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	115.39%
Enterprise Value to Invested Capital (EV/IC)	4.29	4.14	3.75
Enterprise Value to Revenue (EV/Rev)	5.82	7.96	8.34
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-0.49	-0.66	-2.47
Leverage Ratio	1.89	1.51	9.52
Compound Leverage Factor	2.01	1.59	10.59
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	-2.04	-1.26	1.04
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	5.02	5.39	12.31
Quick Ratio	2.75	4.14	11.40
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-9.49	-35	-445
Operating Cash Flow to CapEx	-3,474.40%	-2,768.92%	0.00%
Free Cash Flow to Firm to Interest Expense	-3.73	-15.10	-47.27
Operating Cash Flow to Interest Expense	-4.53	-11.49	-19.89
Operating Cash Flow Less CapEx to Interest Expense	-4.66	-11.90	-19.75
Efficiency Ratios	-	-	-
Asset Turnover	0.17	0.12	0.10
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	7.81	5.48	4.02
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	87	111	114
Invested Capital Turnover	0.65	0.51	-0.68
Increase / (Decrease) in Invested Capital	-23	-3.75	380
Enterprise Value (EV)	374	457	428
Market Capitalization	463	560	756
Book Value per Share	$3.57	$4.28	$6.56
Tangible Book Value per Share	$3.57	$4.28	$6.56
Total Capital	176	213	442
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-88	-102	-327
Capital Expenditures (CapEx)	0.33	0.98	-1.29
Debt-free, Cash-free Net Working Capital (DFCFNWC)	41	6.35	-2.74
Debt-free Net Working Capital (DFNWC)	129	109	325
Net Working Capital (NWC)	129	109	325
Net Nonoperating Expense (NNE)	24	16	-937
Net Nonoperating Obligations (NNO)	-88	-102	-327
Total Depreciation and Amortization (D&A)	3.62	4.26	7.71
Debt-free, Cash-free Net Working Capital to Revenue	63.11%	11.05%	-5.33%
Debt-free Net Working Capital to Revenue	200.34%	189.42%	632.47%
Net Working Capital to Revenue	200.34%	189.42%	632.47%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($1.15)	($1.00)	$11.85
Adjusted Weighted Average Basic Shares Outstanding	48.85M	55.30M	73.59M
Adjusted Diluted Earnings per Share	($1.15)	($1.00)	$11.85
Adjusted Weighted Average Diluted Shares Outstanding	48.85M	55.30M	73.59M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	49.47M	48.16M	62.86M
Normalized Net Operating Profit after Tax (NOPAT)	-30	-37	-55
Normalized NOPAT Margin	-46.14%	-64.96%	-107.86%
Pre Tax Income Margin	-69.30%	-85.80%	-180.76%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-16.52	-19.97	-8.87
NOPAT to Interest Expense	-12.91	-16.69	-6.85
EBIT Less CapEx to Interest Expense	-16.65	-20.38	-8.73
NOPAT Less CapEx to Interest Expense	-13.04	-17.11	-6.71
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.79%	-357.02%	14.77%

This table displays calculated financial ratios and metrics derived from Theravance Biopharma's official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	6.77%	7.49%	3.69%	39.22%	19.91%	26.04%	24.43%	-21.06%	-1.99%	-5.63%
EBITDA Growth	-155.41%	-43.45%	-7.11%	58.99%	73.77%	35.54%	32.18%	42.24%	79.20%	81.70%
EBIT Growth	-88.85%	-35.10%	-7.03%	55.44%	67.96%	39.06%	34.08%	41.66%	75.44%	78.72%
NOPAT Growth	-47.44%	-23.71%	2.59%	55.01%	64.20%	38.32%	30.21%	33.07%	68.97%	73.51%
Net Income Growth	-82.46%	-41.88%	-5.65%	47.19%	17.87%	-100.98%	-91.00%	14.87%	67.65%	2,696.10%
EPS Growth	-55.00%	-52.94%	-21.43%	31.43%	-225.00%	-101.40%	-154.55%	-2.94%	145.71%	2,629.17%
Operating Cash Flow Growth	-5.62%	-109.01%	64.50%	90.89%	99.31%	88.77%	15.57%	56.96%	-192.35%	51.29%
Free Cash Flow Firm Growth	2,826.89%	108.23%	100.79%	99.54%	99.84%	63.64%	-2,796.90%	-1,302.63%	-195.72%	-297.57%
Invested Capital Growth	-21.14%	-15.91%	-13.40%	-5.09%	-3.28%	1,892.88%	128.29%	131.58%	143.01%	98.15%
Revenue Q/Q Growth	11.18%	18.32%	-1.70%	-17.43%	11.93%	14.14%	31.99%	-28.89%	17.65%	12.68%
EBITDA Q/Q Growth	12.23%	36.31%	-58.23%	-234.01%	50.70%	52.45%	39.42%	-84.71%	-21.13%	49.97%
EBIT Q/Q Growth	11.95%	35.36%	-49.16%	-122.47%	37.01%	48.79%	37.91%	-59.99%	-19.79%	44.61%
NOPAT Q/Q Growth	15.11%	31.00%	-40.14%	-79.60%	28.77%	45.67%	35.28%	-42.92%	-22.74%	38.52%
Net Income Q/Q Growth	-22.28%	23.18%	-41.71%	-37.06%	4.92%	42.79%	29.17%	-113.16%	-101.13%	11,290.71%
EPS Q/Q Growth	-19.23%	23.53%	-41.67%	-20.00%	-17.65%	39.29%	20.00%	-318.75%	-98.68%	11,136.36%
Operating Cash Flow Q/Q Growth	82.64%	-17.69%	-332.00%	-19.67%	65.65%	80.01%	-10.83%	90.95%	-460.40%	-50.29%
Free Cash Flow Firm Q/Q Growth	65.24%	149.62%	285.11%	-257.15%	99.50%	76.16%	-9.31%	-21.80%	-14.56%	-1,868.22%
Invested Capital Q/Q Growth	-7.53%	-3.40%	-6.94%	-5.13%	-1.39%	-0.52%	1.98%	-3.32%	1,927.89%	98.43%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-40.53%	-51.34%	-95.38%	-59.26%	-16.94%	-38.47%	-92.33%	-201.16%	-77.45%	-75.22%
Operating Margin	-49.06%	-64.25%	-110.16%	-77.27%	-35.53%	-55.82%	-117.27%	-239.15%	-118.99%	-114.06%
EBIT Margin	-44.24%	-55.86%	-102.25%	-67.39%	-25.01%	-44.44%	-99.05%	-210.55%	-93.58%	-91.91%
Profit (Net Income) Margin	-82.79%	-75.28%	-115.94%	-80.42%	-48.45%	-57.03%	-113.79%	-212.04%	-70.74%	7,361.91%
Tax Burden Percent	173.70%	126.32%	108.59%	112.13%	169.66%	118.03%	110.28%	98.24%	72.67%	-5,720.72%
Interest Burden Percent	107.75%	106.69%	104.42%	106.44%	114.18%	108.73%	104.17%	102.51%	104.01%	140.01%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-22.36%	-27.53%	-45.48%	-30.89%	-12.70%	-40.23%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-12.83%	-23.00%	-41.28%	-28.77%	-10.77%	-39.33%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	6.30%	12.00%	22.96%	18.00%	7.07%	33.60%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-16.06%	-15.53%	-22.52%	-12.89%	-5.63%	-6.64%	-2,494.07%	9,168.35%	1,689.74%	1,083.49%
Cash Return on Invested Capital (CROIC)	-9.60%	-12.56%	-13.54%	-22.29%	-31.55%	-147.55%	-498.56%	-467.06%	-388.84%	0.00%
Operating Return on Assets (OROA)	-7.74%	-9.17%	-15.68%	-9.11%	-2.90%	-4.12%	-12.58%	-22.88%	-9.78%	-8.14%
Return on Assets (ROA)	-14.48%	-12.36%	-17.78%	-10.87%	-5.62%	-5.28%	-14.45%	-23.04%	-7.40%	651.79%
Return on Common Equity (ROCE)	-16.06%	-15.53%	-22.52%	-12.89%	-5.63%	-6.64%	-2,494.07%	9,168.35%	1,689.74%	1,083.49%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-26.61%	-23.57%	-21.85%	0.00%	-23.18%	310.01%	236.40%	0.00%	176.97%
Net Operating Profit after Tax (NOPAT)	-6.44	-7.59	-11	-7.84	-4.37	-6.13	-11	-17	-12	-9.94
NOPAT Margin	-34.34%	-44.97%	-77.11%	-54.09%	-24.87%	-39.07%	-82.09%	-167.40%	-83.29%	-79.84%
Net Nonoperating Expense Percent (NNEP)	-9.53%	-4.54%	-4.20%	-2.12%	-1.93%	-0.91%	-4.04%	-3.60%	1.44%	369.13%
Return On Investment Capital (ROIC_SIMPLE)	-3.67%	-	-	-	-2.05%	-	-	-	-	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	98.65%	100.04%	119.64%	115.44%	88.20%	102.86%	140.21%	184.15%	114.22%	130.73%
R&D to Revenue	50.41%	54.94%	69.82%	61.84%	47.33%	52.96%	68.55%	139.89%	104.77%	79.25%
Operating Expenses to Revenue	149.06%	164.25%	210.16%	177.27%	135.53%	155.82%	217.27%	339.15%	218.99%	214.06%
Earnings before Interest and Taxes (EBIT)	-8.30	-9.42	-15	-9.77	-4.39	-6.97	-14	-22	-14	-11
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-7.60	-8.66	-14	-8.59	-2.98	-6.04	-13	-21	-11	-9.37
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.64	2.12	2.13	2.11	2.63	1.85	2.14	1.84	1.71	1.61
Price to Tangible Book Value (P/TBV)	2.64	2.12	2.13	2.11	2.63	1.85	2.14	1.84	1.71	1.61
Price to Revenue (P/Rev)	7.19	6.24	6.65	7.02	9.75	8.36	11.67	14.04	14.72	15.01
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.69	0.78	0.87	0.91
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	145.19%	128.43%	115.39%	109.74%
Enterprise Value to Invested Capital (EV/IC)	4.29	3.21	3.24	3.17	4.14	2.87	3.82	3.82	3.75	0.00
Enterprise Value to Revenue (EV/Rev)	5.82	4.79	5.10	5.40	7.96	5.90	8.40	8.69	8.34	5.58
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.49	-0.52	-0.56	-0.63	-0.66	-0.85	3.10	-13.53	-2.47	-3.20
Leverage Ratio	1.89	1.78	1.71	1.58	1.51	1.62	-11.59	46.78	9.52	7.43
Compound Leverage Factor	2.04	1.90	1.78	1.68	1.73	1.76	-12.08	47.95	9.90	10.40
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-1.72	-1.94	-1.80	-1.50	-0.89	-0.94	-0.17	0.64	1.42	0.70
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.02	4.97	5.20	5.74	5.39	6.37	7.82	9.98	12.31	3.60
Quick Ratio	2.75	3.90	4.19	4.62	4.14	5.28	6.82	9.21	11.40	3.43
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	17	10	4.11	-2.22	-0.62	-125	-522	-478	-392	-342
Operating Cash Flow to CapEx	-474.74%	-34,640.00%	-12,263.89%	-1,123.08%	-126.14%	-11,838.10%	0.00%	-1,541.35%	-46,637.22%	0.00%
Free Cash Flow to Firm to Interest Expense	26.34	16.27	6.38	-3.53	-1.00	-204.45	-919.62	-868.87	-713.34	-74.79
Operating Cash Flow to Interest Expense	-1.40	-8.25	-6.86	-1.62	-1.37	-4.08	-21.89	-20.40	-225.55	-4.83
Operating Cash Flow Less CapEx to Interest Expense	-1.70	-8.27	-6.91	-1.77	-2.46	-4.12	-21.10	-21.73	-226.04	-4.82
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.17	0.16	0.15	0.14	0.12	0.09	0.13	0.11	0.10	0.09
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	7.81	7.40	7.01	5.91	5.48	5.15	4.64	3.83	4.02	3.70
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	87	94	98	105	111	112	113	111	114	-6.25
Invested Capital Turnover	0.65	0.61	0.59	0.57	0.51	1.03	-0.36	-0.41	-0.68	-0.30
Increase / (Decrease) in Invested Capital	-23	-18	-15	-5.63	-3.75	118	511	460	380	333
Enterprise Value (EV)	374	303	316	332	457	322	431	422	428	288
Market Capitalization	463	394	412	432	560	456	598	682	756	775
Book Value per Share	$3.57	$3.79	$3.98	$4.25	$4.28	$4.66	$4.94	$5.89	$6.56	$6.29
Tangible Book Value per Share	$3.57	$3.79	$3.98	$4.25	$4.28	$4.66	$4.94	$5.89	$6.56	$6.29
Total Capital	176	186	194	205	213	246	280	371	442	481
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-88	-91	-96	-100	-102	-134	-167	-260	-327	-487
Capital Expenditures (CapEx)	0.19	0.02	0.04	0.09	0.68	0.02	-0.45	0.73	0.27	-0.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)	41	1.68	0.28	2.66	6.35	2.32	0.01	-6.11	-2.74	-117
Debt-free Net Working Capital (DFNWC)	129	93	96	103	109	136	167	235	325	370
Net Working Capital (NWC)	129	93	96	103	109	136	167	235	325	370
Net Nonoperating Expense (NNE)	9.09	5.11	5.54	3.82	4.14	2.82	4.36	4.65	-1.84	-927
Net Nonoperating Obligations (NNO)	-88	-91	-96	-100	-102	-134	-167	-260	-327	-487
Total Depreciation and Amortization (D&A)	0.70	0.76	0.98	1.18	1.42	0.94	0.92	0.98	2.36	2.08
Debt-free, Cash-free Net Working Capital to Revenue	63.11%	2.66%	0.46%	4.32%	11.05%	4.25%	0.01%	-12.58%	-5.33%	-227.03%
Debt-free Net Working Capital to Revenue	200.34%	147.24%	155.38%	166.85%	189.42%	250.10%	326.64%	484.18%	632.47%	715.66%
Net Working Capital to Revenue	200.34%	147.24%	155.38%	166.85%	189.42%	250.10%	326.64%	484.18%	632.47%	715.66%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.31)	($0.26)	($0.34)	($0.24)	($0.20)	($0.17)	($0.28)	($0.35)	$0.16	$12.14
Adjusted Weighted Average Basic Shares Outstanding	48.85M	49.04M	48.75M	48.28M	55.30M	52.36M	56.68M	62.93M	73.59M	75.52M
Adjusted Diluted Earnings per Share	($0.31)	($0.26)	($0.34)	($0.24)	($0.20)	($0.17)	($0.28)	($0.35)	$0.16	$12.14
Adjusted Weighted Average Diluted Shares Outstanding	48.85M	49.04M	48.75M	48.28M	55.30M	52.36M	56.68M	62.93M	73.59M	75.52M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	49.47M	49.17M	48.92M	48.63M	48.16M	49.80M	52.81M	57.80M	62.86M	67.37M
Normalized Net Operating Profit after Tax (NOPAT)	-6.44	-6.49	-8.93	-7.84	-4.37	-6.13	-10	-16	-12	-9.59
Normalized NOPAT Margin	-34.34%	-38.49%	-62.62%	-54.09%	-24.87%	-39.07%	-76.14%	-156.83%	-83.29%	-76.98%
Pre Tax Income Margin	-47.66%	-59.59%	-106.77%	-71.72%	-28.56%	-48.32%	-103.19%	-215.83%	-97.34%	-128.69%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-12.90	-14.96	-22.64	-15.54	-7.05	-11.45	-23.98	-39.88	-24.93	-2.50
NOPAT to Interest Expense	-10.02	-12.04	-17.07	-12.47	-7.01	-10.07	-19.87	-31.71	-22.18	-2.17
EBIT Less CapEx to Interest Expense	-13.20	-14.98	-22.69	-15.68	-8.14	-11.49	-23.18	-41.20	-25.41	-2.49
NOPAT Less CapEx to Interest Expense	-10.31	-12.06	-17.13	-12.62	-8.10	-10.10	-19.08	-33.03	-22.67	-2.16
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.79%	-62.16%	-134.93%	-317.50%	-357.02%	-353.37%	30.48%	21.03%	14.77%	11.06%

Frequently Asked Questions About Theravance Biopharma's Financials

When does Theravance Biopharma's financial year end?

According to the most recent income statement we have on file, Theravance Biopharma's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Theravance Biopharma's net income changed over the last 2 years?

Theravance Biopharma's net income appears to be on a downward trend, with a most recent value of -$56.42 million in 2024, falling from $872.13 million in 2022. The previous period was -$55.19 million in 2023. See where experts think Theravance Biopharma is headed by visiting Theravance Biopharma's forecast page.

What is Theravance Biopharma's operating income?

Theravance Biopharma's total operating income in 2024 was -$46.95 million, based on the following breakdown:

Total Gross Profit: $64.38 million
Total Operating Expenses: $111.33 million

How has Theravance Biopharma revenue changed over the last 2 years?

Over the last 2 years, Theravance Biopharma's total revenue changed from $51.35 million in 2022 to $64.38 million in 2024, a change of 25.4%.

How much debt does Theravance Biopharma have?

Theravance Biopharma's total liabilities were at $178.62 million at the end of 2024, a 5.7% increase from 2023, and a 7.9% increase since 2022.

How much cash does Theravance Biopharma have?

In the past 2 years, Theravance Biopharma's cash and equivalents has ranged from $37.80 million in 2024 to $298.17 million in 2022, and is currently $37.80 million as of their latest financial filing in 2024.

How has Theravance Biopharma's book value per share changed over the last 2 years?

Over the last 2 years, Theravance Biopharma's book value per share changed from 6.56 in 2022 to 3.57 in 2024, a change of -45.6%.

Related Companies

This page (NASDAQ:TBPH) was last updated on 6/4/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Theravance Biopharma (TBPH) Financials

Frequently Asked Questions About Theravance Biopharma's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Theravance Biopharma (TBPH) Financials

Annual Income Statements for Theravance Biopharma

Quarterly Income Statements for Theravance Biopharma

Annual Cash Flow Statements for Theravance Biopharma

Quarterly Cash Flow Statements for Theravance Biopharma

Annual Balance Sheets for Theravance Biopharma

Quarterly Balance Sheets for Theravance Biopharma

Annual Metrics And Ratios for Theravance Biopharma

Quarterly Metrics And Ratios for Theravance Biopharma

Frequently Asked Questions About Theravance Biopharma's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools